Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04313361
Other study ID # CR108767
Secondary ID NOPRODLUC4001
Status Completed
Phase
First received
Last updated
Start date May 6, 2020
Est. completion date December 9, 2021

Study information

Verified date January 2022
Source Johnson & Johnson (China) Investment Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to assess the current smoking status and smoking cessation attempts among smokers or recent smoking quitters during the perioperative period, to describe postoperative pulmonary complications (PPCs) and other postoperative complications (PCs) following a lung surgery, and to describe the smoking cessation methods and services patients received from their health care professionals (HCPs) and participant's satisfaction among participants with lung cancer, chronic obstructive pulmonary disorder (COPD), a pulmonary lesion (example, nodule, or ground glass opacity) or other pulmonary conditions who are admitted to the thoracic surgical unit of the participating hospitals in China.


Recruitment information / eligibility

Status Completed
Enrollment 290
Est. completion date December 9, 2021
Est. primary completion date December 9, 2021
Accepts healthy volunteers No
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria: - Participants who have been scheduled for an elective lung surgery by the treating physician's judgement, due to the following conditions: known lung cancer, COPD, a pulmonary lesion (example. nodule, ground glass opacity) or other pulmonary conditions - Smokers who are or were smoking on average no fewer than 5 cigarettes per day for equal or more than 3 years within 3 months prior to the scheduled surgery, or recent smoking quitters with a history of smoking on average no fewer than 5 cigarettes per day for equal or more than 3 years, who quit smoking between 3 months and 5 years prior to the scheduled surgery - Being willing to participate the study and sign the participant informed consent form (ICF) Exclusion Criteria: - Participants who have emergency lung surgery due to accident or injury - Participants are not likely to be able to complete the 6-month follow-up after the lung surgery

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No intervention
No drug will be administered as part of this study.

Locations

Country Name City State
China Xuanwu Hospital, Capital Medical University Beijing
China The First Affiliated Hospital of Guangzhou Medical University Guangzhou
China Ruijin Hospital, Shanghai Jiao Tong University Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Johnson & Johnson (China) Investment Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Smokers and Recent Smoking Quitters at Baseline Prior to the Surgery Percentage of smokers and recent smoking quitters at baseline prior to the surgery will be reported. Baseline Prior to the Surgery
Primary Smoking Dependence Among Smokers as Measured by Fagerstrom Test of Nicotine Dependence (FTND) Scale at Baseline Prior to the Surgery Level of smoking dependence will be measured by FTND Scale in the participant's questionnaire. FTND is a 6-item self-report measure of nicotine dependence derived from the Fagerström Tolerance Questionnaire, which comprises yes/no options (scored from 0 to 1) and multiple-choice items (scored from 0 to 3). The items are summed to yield a total score of 0-10. The higher the total Fagerström score, the more intense is the participant's physical dependence on nicotine. Baseline Prior to the Surgery
Primary Smoking Dependence Among Smokers as Measured by FTND Scale at Month 1 Post-surgery Level of smoking dependence will be measured by FTND Scale in the participant's questionnaire. FTND is a 6-item self-report measure of nicotine dependence derived from the Fagerström Tolerance Questionnaire, which comprises yes/no options (scored from 0 to 1) and multiple-choice items (scored from 0 to 3). The items are summed to yield a total score of 0-10. The higher the total Fagerström score, the more intense is the participant's physical dependence on nicotine. Month 1 post-surgery
Primary Smoking Dependence Among Smokers as Measured by FTND Scaleat Month 3 Post-surgery Level of smoking dependence will be measured by FTND Scale in the participant's questionnaire. FTND is a 6-item self-report measure of nicotine dependence derived from the Fagerström Tolerance Questionnaire, which comprises yes/no options (scored from 0 to 1) and multiple-choice items (scored from 0 to 3). The items are summed to yield a total score of 0-10. The higher the total Fagerström score, the more intense is the participant's physical dependence on nicotine. Month 3 post-surgery
Primary Smoking Dependence Among Smokers as Measured by FTND Scaleat Month 6 Post-surgery Level of smoking dependence will be measured by FTND Scale in the participant's questionnaire. FTND is a 6-item self-report measure of nicotine dependence derived from the Fagerström Tolerance Questionnaire, which comprises yes/no options (scored from 0 to 1) and multiple-choice items (scored from 0 to 3). The items are summed to yield a total score of 0-10. The higher the total Fagerström score, the more intense is the participant's physical dependence on nicotine. Month 6 post-surgery
Primary Number of Smoking Cessation Attempts at Baseline Prior to the Surgery Number of smoking cessation attempts at baseline prior to the surgery will be reported. Baseline prior to the surgery
Primary Number of Smoking Cessation Attempts at Month 1 Post-surgery Number of smoking cessation attempts at Month 1 post-surgery will be reported. Month 1 post-surgery
Primary Number of Smoking Cessation Attempts at Month 3 Post-surgery Number of smoking cessation attempts at Month 3 post-surgery will be reported. Month 3 post-surgery
Primary Number of Smoking Cessation Attempts at Month 6 Post-surgery Number of smoking cessation attempts at Month 6 post-surgery will be reported. Month 6 post-surgery
Primary Number of Participants who Used Methods and Medications for Smoking Cessation at Baseline Number of participants who used prior methods and medications for smoking cessation at baseline will be reported. Baseline
Primary Number of Participants who Used Current Methods and Medications for Smoking Cessation at Month 1 Post-surgery Number of participants who used current methods or medication for smoking cessation at Month 1 post-surgery will be reported. Month 1 post-surgery
Primary Number of Participants who Used Current Methods and Medications for Smoking Cessation at Month 3 Post-surgery Number of participants who used current methods or medication for smoking cessation at Month 3 post-surgery will be reported. Month 3 post-surgery
Primary Number of Participants who Used Prior Methods and Medications for Smoking Cessation at Month 6 Post-surgery Number of participants who used current methods or medication for smoking cessation at Month 6 post-surgery will be reported. Month 6 post-surgery
Primary Percentage of Participants Using Nicotine Replacement Therapy (NRTs) at Baseline Prior to Surgery Percentage of participants using NRTs, types of NRTs used and perceived effectiveness, at baseline prior to surgery will be reported. Baseline prior to surgery
Primary Percentage of Participants Using NRTs at Month 1 Post-surgery Percentage of participants using NRTs, types of NRTs used and perceived effectiveness, at Month 1 post surgery will be reported. Month 1 post-surgery
Primary Percentage of Participants Using NRTs at Month 3 Post-surgery Percentage of participants using NRTs, types of NRTs used and perceived effectiveness, at Month 3 post surgery will be reported. Month 3 post-surgery
Primary Percentage of Participants Using NRTs, Types of NRTs Used and Perceived Effectiveness at Month 6 Post-surgery Percentage of participants using NRTs, types of NRTs used and perceived effectiveness, at Month 6 post surgery will be reported. Month 6 post-surgery
Primary Percentage of Participants with Self-reported Smoking Abstinence and Point Prevalence at Month 1 Post-surgery Percentage of participants with self-reported smoking abstinence and 7-days/30-day point prevalence of smoking at Month 1 post-surgery will be reported. Month 1 post-surgery
Primary Percentage of Participants with Self-reported Smoking Abstinence and Point Prevalence at Month 3 Post-surgery Percentage of participants with self-reported smoking abstinence and point prevalence of smoking at Month 3 post-surgery will be reported. Month 3 post-surgery
Primary Percentage of Participants with Self-reported Smoking Abstinence and Point Prevalence at Month 6 Post-surgery Percentage of participants with self-reported smoking abstinence and point prevalence of smoking at Month 6 post-surgery will be reported. Month 6 post-surgery
Primary Percentage of Participants with Smoking Relapse at Month 1 Post-surgery Percentage of participants with smoking relapse at Month 1 post-surgery will be reported. Month 1 post-surgery
Primary Percentage of Participants with Smoking Relapse at Month 3 Post-surgery Percentage of participants with smoking relapse at Month 3 post-surgery will be reported. Month 3 post-surgery
Primary Percentage of Participants with Smoking Relapse at Month 6 Post-surgery Percentage of participants with smoking relapse at Month 6 post-surgery will be reported. Month 6 post-surgery
Primary Overall Incidence of Postoperative Complications (PCs) and Postoperative Pulmonary Complications (PPCs) Post-surgery (at 1 Day Prior to Discharge)and by Baseline Smoking Status Overall incidence of PCs and PPCs post-surgery (at 1 day prior to discharge) and by baseline smoking status will be reported. At 1 day prior to discharge
Primary Overall Incidence of PCs and PPCs Post-surgery (Within 2 Weeks After Surgery) and by Baseline Smoking Status Overall incidence of PCs and PPCs post-surgery (within 2 weeks after surgery) and by baseline smoking status will be reported. Within 2 weeks after surgery
Primary Overall Incidence of PCs and PPCs Post-surgery (Within 1 Month Post-surgery) and by Baseline Smoking Status Overall incidence of PCs and PPCs post-surgery (within 1 month post-surgery) and by baseline smoking status will be reported. Within 1 month post-surgery
Primary Overall Incidence of PCs and PPCs Post-surgery (Within 3 Months Post-surgery) and by Baseline Smoking Status Overall incidence of PCs and PPCs post-surgery (within 3 months post-surgery) and by baseline smoking status will be reported. Within 3 months post-surgery
Primary Overall Incidence of PCs and PPCs Post-surgery (Within 6 Months Post-surgery) and by Baseline Smoking Status Overall incidence of PCs and PPCs post-surgery (within 6 months post-surgery) and by baseline smoking status will be reported. Within 6 months post-surgery
Primary Percentage of Participants who Received Advice from HCPs to Quit Smoking at Baseline Prior to Surgery Percentage of participants who received advice from HCPs to quit smoking at baseline prior to surgery will be reported. Baseline prior to surgery
Primary Percentage of Participants who Received Advice from HCPs to Quit Smoking at Month 1 Post-surgery Percentage of participants who received advice from HCPs to quit smoking at Month 1 post-surgery will be reported. Month 1 post-surgery
Primary Percentage of Participants who Received Advice from HCPs to Quit Smoking at Month 3 post-surgery Percentage of participants who received advice from HCPs to quit smoking at Month 3 post-surgery will be reported. Month 3 post-surgery
Primary Percentage of Participants who Received Advice from HCPs to Quit Smoking at Month 6 post-surgery Percentage of participants who received advice from HCPs to quit smoking at Month 6 post-surgery will be reported. Month 6 post-surgery
Primary Percentage of Specific Smoking Cessation Methods and Service Participants Received from HCPs at Baseline Prior to Surgery Percentage of specific smoking cessation methods and service participants received from HCPs at baseline prior to surgery will be reported. Baseline prior to surgery
Primary Percentage of Specific Smoking Cessation Methods and Service Participants Received from HCPs at Baseline Prior to Surgery Percentage of specific smoking cessation methods and service participants received from HCPs at Month 1 post-surgery will be reported. Month 1 post-surgery
Primary Percentage of Specific Smoking Cessation Methods and Service Participants Received from HCPs at Month 3 post-surgery Percentage of specific smoking cessation methods and service participants received from HCPs at Month 3 post-surgery will be reported. Month 3 post-surgery
Primary Percentage of Specific Smoking Cessation Methods and Service Participants Received from HCPs at Month 6 post-surgery Percentage of specific smoking cessation methods and service participants received from HCPs at Month 6 post-surgery will be reported. Month 6 post-surgery
Primary Percentage of Participant's Satisfaction on the Smoking Cessation Methods Received from HCPs at Baseline Prior to Surgery Percentage of participant's satisfaction on the smoking cessation methods received from HCPs at baseline prior to surgery will be reported. Baseline prior to surgery
Primary Percentage of Participant's Satisfaction on the Smoking Cessation Methods Received from HCPs at Month 1 Post-surgery Percentage of participant's satisfaction on the smoking cessation methods received from HCPs at Month 1 post-surgery will be reported. Month 1 post-surgery
Primary Percentage of Participant's Satisfaction on the Smoking Cessation Methods Received from HCPs at Month 3 Post-surgery Percentage of participant's satisfaction on the smoking cessation methods received from HCPs at Month 3 post-surgery will be reported. Month 3 post-surgery
Primary Percentage of Participant's Satisfaction on the Smoking Cessation Methods Received from HCPs at Month 6 Post-surgery Percentage of participant's satisfaction on the smoking cessation methods received from HCPs at Month 6 post-surgery will be reported. Month 6 post-surgery
See also
  Status Clinical Trial Phase
Completed NCT05043428 - The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD N/A
Completed NCT00528996 - An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler. Phase 2
Completed NCT03740373 - A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate Phase 1
Completed NCT05402020 - Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
Completed NCT05393245 - Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
Completed NCT04011735 - Re-usable Respimat® Soft MistTM Inhaler Study
Enrolling by invitation NCT03075709 - The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
Completed NCT03764163 - Image and Model Based Analysis of Lung Disease Early Phase 1
Completed NCT00515268 - Endotoxin Challenge Study For Healthy Men and Women Phase 1
Completed NCT04085302 - TARA Working Prototype Engagement Evaluation: Feasibility Study N/A
Completed NCT03691324 - Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study N/A
Completed NCT02236611 - A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT00153075 - Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT01017952 - A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT01009463 - A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT04882124 - Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD Phase 2
Completed NCT02853123 - Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients Phase 4
Completed NCT02619357 - Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma Phase 1
Recruiting NCT05858463 - High Intensity Interval Training and Muscle Adaptations During PR N/A
Not yet recruiting NCT05032898 - Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II